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Abstract
Background
During the period 1985-2000 the breast cancer incidence rates increased 50% in the age
group invited to mammography screening in Norway and Sweden. Simultaneously, use of
hormone replacement treatment therapy (HT) increased 5 times. Several influential obser-
vational studies showed that HT was associated with 50% to 100% increased risk of breast
cancer and most for those using combined (estrogen plus progestin) hormone replacement
therapy (CHT). In contrast, the randomized WHI trial reported that CHT increased the risk
by 10% for those not having previously used hormones and 24% when including previous
users in the analyses. In another randomized trial, estrogen use only was not associated
with any increased risk at all. After the WHI trial was published in 2003, use of HT dropped
70% within 5 years in Norway and Sweden while breast cancer rates were essentially un-
changed. After 2008, HT use has dropped further and breast cancer incidence rates have
started increasing again. The study objective is to calculate and to explain potential bias in
the observational study design.
Methods and Findings
Here we use data from the randomized WHI trial and analyze these data as done in the ob-
servational studies to calculate the magnitude of the potential biases in the observational
study design. Time varying effect of hormones and categorization of the follow-up time may
increase the hazard ratio for long-term users from 1.10 to 1.48. Selective retrospective re-
porting of hormone use may further increase the hazard ratio to 1.68.
Conclusions
We suggest that the mechanism causing higher hazard ratio of breast cancer (compared to
the observational studies) is the time-varying effect of CHT on the breast cancer risk and se-
lective retrospective reporting of hormone use. Other risk factors for the increase in breast
cancer risk in the age group 50-69 years should be considered, for example, overdiagnosis.
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Introduction
In the period 1985–2000 breast cancer incidence increased about 50% in the age groups invited
to screening [1]. Simultaneously several important observational studies reported large in-
creases in breast cancer risk among women using hormone replacement therapy (HT); the Mil-
lion Woman (MW) study [2] reported a 100% increase of invasive breast cancers among
current users of combined (estrogen plus progestin) hormone replacement therapy (CHT) and
similar increases were observed in two observational studies from Norway with estimated pop-
ulation attributable fractions of 14% and 27%, respectively [2–4]. Use of estrogen only was as-
sociated with a lower risk. After screening was introduced in Norway, HT use dropped 70%
within 5 years, while breast cancer incidence rates were constant [5–7]. A similar trend was ob-
served in Sweden [7,8]. If CHT was the main cause for the incidence increase before year 2000,
then we would expect breast cancer rates to fall dramatically when 70% of women suddenly
stop using CHT. Moreover, in the period 2007–12 breast cancer risks in the screened age group
has increased further (from 275 per 100,000 to about 320 per 100,000 women in Norway and
Sweden) [7,8], while use of CHT has kept on falling [5].
In contrast to the observational studies, the Women’s Health Initiative (WHI) trial reported
only 24% increased risk of invasive breast cancer after on average 5.6 years follow-up among
women randomized to CHT [9]. Among women with no exposure to hormone therapy before
randomization, there was only 10% incidence increase in the treatment group. The WHI trial
reported no significant effect of estrogen only on the breast cancer incidence [10].
Another important observation in the WHI trial was that CHT had a biphasic effect on the
breast cancer incidence. Compared to the control group, the incidence was temporarily re-
duced by 41% in the first 2 years of the follow-up (calculated from table 2 in [9]) for women
with no prior exposure to CHT. It was also a significant time-varying effect for those with a his-
tory of prior exposure to CHT. The most likely explanation of this time-varying effect is that
CHT increases the breast tissue density causing reduced sensitivity at mammography leading
to an initial reduction in the detection of small breast tumors [11]. After 2 years follow-up, a
strong increase in the numbers of breast cancer was observed in the CHT group and the tumors
were also on average larger. A substantial part of the increase after 2 years follow-up may be ac-
cumulated tumors that have escaped detection during the first 2 years.
Another problem in observational studies is that some people reporting no CHT use at
study start will start using hormones during the follow-up. Usually, unreported CHT use
among women assumed not to be using CHT (typically the reference group in an observational
study), leads to an underestimation of the drug effect. However, in this case and very contra-in-
tuitively, it causes overestimation because an influx of women who use CHT for less than three
years and who have lower breast cancer risks than no-users.
Retrospectively reporting the length of drug use may be associated with information bias
[12]. Finally we show that information bias also may lead to overestimation of the CHT effect
in an observational study and this overestimation is also related to the biphasic effect of CHT.
The objective is to quantify the sizes of bias in observational studies of CHT and breast can-
cer using 3 different realistic scenarios all with 3 years follow-up. We use data from the more
reliable randomized WHI trial [9] to calculate the magnitude of the potential biases in the MW
study and other similar studies [2–4].
Data and Methods
In the WHI trial 8506 women were randomized to CHT and 8102 to placebo treatment [9].
After excluding 4304 women with exposure to CHT before randomization, there were 6277 in
the CHT group and 6020 in the placebo group. In the latter subgroups, there were diagnosed
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41 breast cancers in the CHT group and 55 in the placebo group in the first 3 years of follow-
up. The corresponding cumulative breast cancer incidence rates were 660 and 930 per 100,000.
In the next 3 years of the follow-up, there were another 100 breast cancers in the CHT group
and 66 in the placebo group and the corresponding cumulative rates after 6 years were 2470
and 2230 respectively (Fig 1). The hazard ratio (HR) among CHT users were 0.71 (660/930)
and 1.10 (2470/2230) after 3 and 6 years follow-up, respectively [9]. Below we assume these
time-varying incidence rates are true and unbiased.
Based on the incidence rates in the WHI trial, we constructed 3 data sets (or scenarios)
which we later used in observational studies with similar follow-up and categorization of CHT
users as reported in the observational studies [2–4]. First note that the average follow-up time
is 3 years the observational studies but 5.6 years in the randomized trial [2–4,9]. At study start
we assume that women could have used CHT for 0–1 or 1–5 years in our fictional observation-
al study. The average time on CHT for women reporting 0–1 and 1–5 years use at study start
and with 3 years follow-up is therefore 3.5 and 6 years respectively in our data set (Fig 2).
When constructing the data set for our observational study, we assumed that the duration
of CHT use at study start was uniformly distributed over 0–12 months for the short-time users
(group A in Fig 2) and over 1–5 years for long-time users (group B in Fig 2). Thus, the differ-
ence in the mean age for groups A and B is 2.5 years (which is the same as the difference in
mean duration time of CHT use in the two groups). The maximum follow-up in the WHI trial
was 7 years and with a joint incidence estimate for the 6-7th year. The constructed population
Fig 1. Cumulative breast cancer incidence rates for women in the WHI trial that had not used CHT previous to the randomization.
doi:10.1371/journal.pone.0124076.g001
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data included women who had used CHT for 0–5 years at entry and with 3 years follow-up and
the maximum time on CHT is 8 years. Therefore, we had to assume that the incidence rate in
the 8th year of follow-up was as in the 6-7th year. We had no data to study the bias for women
who had used CHT for longer than 5 years at study start.
The numbers of breast cancers in the constructed data sets are given in Tables 1–3, and the
numbers are calculated from the Table 2 in Chlebowski et al [9]. In the second column in
Table 1 (scenario 1), the numbers of breast cancers for short time CHT users (group A) are
Fig 2. Womenwho have used CHT in 3 to 4 years are referred to as Group A; women who have used CHT in 4 to 9 years are referred to as group B.
The arrows indicate the individual follow-up periods from first starting using CHT. In a randomized trial women are followed from time zero to the end of the
arrows. In the observational studies women are only followed in the red and blue coloured part of the arrows. If the breast incidence is time-varying, then this
will lead to systematic shift of diagnosis from the black part of the arrows to the coloured part of the arrows because of delay in time of diagnosis. This is
leading to an over-estimation of the hazard rates in the period indicated by red and blue colours.
doi:10.1371/journal.pone.0124076.g002
Table 1. (Scenario 1) The number of breast cancer cases in the intervention group for the short term users (Group A) and long term users (Group
B).
Time Breast cancers Time Breast cancers
Group A Control Group B Control
1 11 18 3.5 27 20.75
2 17 20.5 4.5 32 22.13
3 27 21 5.5 34.5 23.38
The numbers of CHT users were 6277, and there were 6020 in the control group. The time variable is time since randomization.
doi:10.1371/journal.pone.0124076.t001
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given: the numbers in the first year of the follow-up in Table 1 is the average number of breast
cancers in the 2 first years of the follow-up in the WHI trial (this is calculated as (7+15)/
2 = 11); the second year of follow-up in Table 1 is the average number of breast cancers in the
second and third year of the follow-up in the WHI trial (this is calculated as (15+19)/2 = 17);
and the third year of follow-up is the average of the third and fourth year of follow-up in the
WHI trial (this is calculated as (19+35)/2 = 27). In the fifth column in Table 1 the numbers of
breast cancers for long time CHT users (group B) are given; the number of breast cancers in
the first year of follow-up in Table 1 is calculated as the average number of breast cancers in
the period 2.5–6.5 years in the WHI trial and this is calculated as (0.515+19+35+28+0.537)/
4 = 27; the number of breast cancers in the second year of the follow-up is calculated as the av-
erage number of breast cancers in the period 3.5–7.5 years in the WHI trial and this is calculat-
ed as (0.519+35+28+37+0.537)/4 = 32; and the number of breast cancers in the third year of
the follow-up in Table 1 is calculated as the average number of breast cancers in the period
4.5–8.5 years in the WHI trial and this is calculated as (0.535+28+37+37+0.537)/4 = 34.5. The
numbers in the third and sixth columns in Table 1 are calculated analogously as above but
using data from the placebo group. Note that the time-varying incidence rates automatically
adjust for the time variable in the first and forth columns.
Sales figures of CHT in Norway increased from 10 to 40 Defined Daily Doses (DDD)/day
per 1000 women in the period 1991–2000 [5,7]; i.e. the user prevalence increased from 5% to
about 20% if all hormones were used in the age group 50–69 years. If we also assume women in
the age group 50 to 69 years use CHT for 2 years on average, then there must be about 9% new
users annually to increase the user frequency from 5% to 20% over 5 years. Thus, it is reason-
able to assume there are 10% new users every year in the non-user group; i.e. there are 30%
new users over 3 years and we assume these women have 50% reduced risk of breast cancers
because they are short term users. In Table 2 (scenario 2) we have adjusted the number of
breast cancers in the control group for new users after study start by multiplying the numbers
in columns 3 and 6 in Table 1 by 0.85.
Table 3. (Scenario 3) The number of breast cancer cases in the intervention group for the short term users (Group A) and long term users (Group
B).
Time Breast cancers Time Breast cancers
Group A Control Group B Control
1 19 25.5 3.5 37.88 25.13
2 27.5 27 4.5 42.25 25.63
3 36.5 24.5 5.5 44.38 26.75
The numbers of CHT users were 8506, and there were 8102 in the control group. The time variable is time since randomization.
doi:10.1371/journal.pone.0124076.t003
Table 2. (Scenario 2) The number of breast cancer cases in the intervention group for the short term users (Group A) and long term users (Group
B).
Time Breast cancers Time Breast cancers
Group A Control Group B Control
1 11 15.3 3.5 27 17.64
2 17 17.43 4.5 32 18.81
3 27 17.85 5.5 34.5 19.87
The numbers of CHT users were 6277, and there were 6020 in the control group. The time variable is time since randomization.
doi:10.1371/journal.pone.0124076.t002
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In Table 3 (scenario 3), we also assumed that a similar number of women as in the WHI
trial had used CHT before entry into the observational study. In second column the numbers
of breast cancers for short time CHT users (group A) are given: the numbers in the first year of
the follow-up in Table 3 is the average number of breast cancers in the 2 first years of the fol-
low-up in the WHI trial (this is calculated as (12+26)/2 = 19); the second year of follow-up is
the average number of breast cancers in the second and third year of the follow-up in the WHI
trial (this is calculated as (26+29)/2 = 27.5); and the third year of follow-up is the average of the
third and fourth year of follow-up in the WHI trial (this is calculated as (29+44)/2 = 36.5). In
the fifth column in Table 3 the numbers of breast cancers for long time CHT users (group B)
are given; the number of breast cancers in the first year of follow-up in is calculated as the aver-
age number of breast cancers in the period 2.5–6.5 years in the WHI trial and this is calculated
as (0.526+29+44+43+0.545)/4 = 37.88; the number of breast cancers in the second year of the
follow-up is calculated as the average number of breast cancers in the period 3.5–7.5 years in
the WHI trial and this is calculated as (0.529+44+43+45+0.556)/4 = 42.25; and the number
of breast cancers in the third year of the follow-up in Table 3 is calculated as the average num-
ber of breast cancers in the period 4.5–8.5 years in the WHI trial and this is calculated as
(0.544+43+45+45+0.545)/4 = 44.38. The numbers in the third and sixth columns in Table 3
are calculated analogously as above but using data from the placebo group.
We used 6277 as the number of individuals at risk in groups A and B, and 6020 for the con-
trol groups in Tables 1 and 2. In Table 3, we used 8506 (CHT users) and 8102 (non-users) as
the number of individuals, respectively.
We used Poisson regression to calculate HR in the observational study with 3 year follow of
women who had no prior CHT-exposure (Table 4) first using data in Table 1 (scenario 1). We
then repeated the regression analysis under the assumption that during each year of the follow-
up, 10% of the non-users started using CHT (using data in Table 2, scenario 2). Finally we did
the analysis under the assumption that the incidence rates in the constructed data set were
identical to that observed for all 16 608 women in the WHI trial (scenario 3); i.e. we assumed
that 26% of the women had previously used CHT but did not correct for previous use (using
data in Table 3). We also calculated the numbers of breast cancers when assuming that only
5% of the non-users started using CHT after the start of the follow-up; the calculated HRs for
these numbers are given in parenthesis in Table 4.
In the observational studies, many women in the non-user group started using CHT during
the follow-up period [2–4]. In the WHI trial the control group received placebo treatment, and
it was therefore assumed that very few started using CHT in the follow-up period. By using the
Table 4. Hazard ratios of breast cancer when data from the randomizedWHI study are analyzed as a
fictive observational study.
Duration of CHT use at baseline Model
1 2 3
0-1 year 0.96 1.14 (1.04) 1.30 (1.21)
1-5 years 1.27 1.48 (1.37) 1.68 (1.69)
Model 1 is a regression model with 3 year follow-up (scenario 1); model 2 is the same model assuming that
10% starts using hormones every year in the non-user group (scenario 2); in model 3 (scenario 3) it is
assumed that the incidence rates in the ﬁctive study were identical to that observed for all 16 608 women of
the WHI trial. In parenthesis we also give HR when assuming that 5% start using hormones every year in
the non-user groups.
doi:10.1371/journal.pone.0124076.t004
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rates in the WHI trial, we have indirectly assumed that the relative number of women who
stopped using CHT is as in the WHI trial [9].
Results
In the constructed observational study, the HRs of breast cancer for women who had used
CHT for less than 1 year and for 1–5 years at entry were 0.96 and 1.27, respectively (Table 4,
model 1), while the unbiased estimates were 0.70 and 1.10. The average duration of CHT for
the long-term users is 6 years (compared to 5.6 years in the WHI study). Assuming that 10% of
the non-users start using CHT every year during the 3-year follow-up period, the HRs were
1.14 and 1.48, respectively (Table 4, model 2). Under the assumption that the incidence rates in
our constructed observational study were identical to that observed for all women in the WHI
trial, the calculated HRs were 1.30 and 1.68, respectively (Table 4, model 3).
We also calculated HR when only 5% of the non-users started using CHT in each year of
the follow-up period (Table 4). The HRs for those who had not used CHT prior to randomiza-
tion were 1.04 (short term users) and 1.37 (long-term users). The corresponding HR when also
including those who had used CHT prior to randomization were 1.21 and 1.69 respectively.
A simple calculation demonstrates that the numbers in Table 1 can be analysed as in the
randomized WHI trial and with a similar result: For group A (and the corresponding control
group), each number is the average over 2 years; this means that the sum after 3 years is the
number of breast cancers from 0.5 to 3.5 years in the WHI trial. The sum over 3 years for
group A is 55 and for group B it is 93.5. For the respective control groups the sums are 59.5 and
66.26, respectively. This gives HR = ((55+93.5)/6277)/((59.5+66.26)/6020) = 1.13 after 6 year
follow-up, which is very close to the 1.10 in the WHI trial [9].
Discussion
We show that the discrepancy between the randomized WHI trial and the observational studies
can be explained by bias in observational studies with short follow-up. First, when analyzing
the data in the WHI trial using an observational study design, HR increases from 1.10 to 1.27
in the long-term users (model 1). The difference in HRs is caused by differences in the start of
follow-up and in the length of the follow-up: all women have used CHT for 6 years in the ran-
domized study design and follow-up starts from time of randomization, while in the observa-
tional design (model 1) long-term users have used CHT on average for 6 years (varying from 4
to 8 years) but the follow-up starts 1–5 years after randomization and the follow-up is 3 years.
A combination of time-varying incidence rates and the influx of new CHT users in the non-
user group after study start decreases the incidence in non-users leading to a further increase of
the HR from 1.27 to 1.48 (model 2). Usually, drug use in the control group leads to an underes-
timation of the difference; however, in this case the effect is the opposite of what is intuitively
expected: the difference is overestimated. Furthermore, retrospectively recording the length
(leading to information bias) of the CHT use causes a further increase from 1.48 to 1.68 (model
3). The WHI study also reported higher HR when adjusting for low adherence, which may ex-
plain further differences; however, we are not able to quantify these.
An alternative interpretation of model 3 is that the sum of a time-varying affect of CHT on
the incidence rate (no effect in the first 2 years and then a strong effect in the next 4 years with
a 24% incidence increase after 6 years follow-up) and with an influx of new CHT users in the
non-user group after study start causes the HR to increase from 1.24 to 1.68.
Our assumption that long term users have higher risk than short term users is crucial for
our analysis and it is actually supported by the observational studies too [2–4]. However, after
about 5 years use there is little evidence for any further increase in risk [2]. Therefore, the bias
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will decline when the follow-up increases to more than 3 years. Our analysis is not very sensi-
tive to the proportion of new users: In parenthesis in Table 4 we also give HR when assuming
that only 5% of non-users start using CHT every year. Our estimates are almost not affected by
changing the annual numbers of new users from 10% to 5%, showing that with 3 years follow-
up it is the biphasic rate rather than the prevalence of new users that is causing bias.
From year 2002 to 2007 use of HT (including CHT) dropped 70% to the level of 1990 in
Norway, while the breast cancer incidence rate was essentially unchanged [5,7]. In the same pe-
riod the decline in the breast cancer incidence in the UK was about 5% in the age group 50 to
59 years [13]. The decline in breast cancer incidence in Sweden was 7.5% for the age group 50–
69 years in the period 2002–7 [7,8]. After 2007 breast cancer incidence rates in the screened
age groups in Norway and Sweden have increased another 15% [6,8] and HT use have kept on
falling [5] which additionally underlines there must other causes for the increase of breast can-
cer in the last 3 decades, for example overdiagnosis [1].
One may argue that there are major differences in the age composition in the studies.
Women in the WHI trial were older than women in the observational studies; however, there
were no significant age difference in the WHI trial [9]. It has been suggested that the difference
may be explained by “gap time” effect [14]; the gap time is time from menopause to first use of
CHT. The gap time model is sensitive to modeling assumptions and furthermore, because two
thirds of data comes from the observational WHI study, the model is essentially an
observational study.
In our regression analyses we have adjusted for a 2.5 years difference in age between the
control group and the CHT users groups. Without age adjustment the HR would have been
about 0.1 higher for women that had used CHT for 1 to 5 years at baseline, but the HR would
have been lower for women who had used CHT for 0 to 1 years.
If for example 20% of women aged 50 to 69 years were using CHT and the breast cancer in-
cidence increases is as in the WHI trial [9], the total incidence increase will be about 5% if all
women use it for 6 years or more. When women stop using CHT, the incidence rate dropped
back to normal within 1–2 years in the WHI trial [15] and the same was observed in the MW
study [2].
The average length on HT varies between studies. In the WHI observational study women
had used CHT for on average 6.9 years at entry and were followed-up in 7 years [14]. This is
much longer than in the randomized WHI trial [9] and the MW study [2]. Furthermore, there
were 145 000 past users and 278 000 current users (median time on HT is 5 years) in the MW
study. In the UK, the HT use is dominated by women who used HT for less than 5 years [2]. A
much smaller incidence decline in Europe than in US may be explained by differences in how
long women have used HT.
In contrast to Europe, a much larger decline was reported in the US after the release of the
WHI study [16]. But it is also possible that less frequent use of mammography may have con-
tributed to the decline. Breen et al. [17] reported a decline from 78% to 72% in the US mam-
mography activity after age 50 occurring about year 2002. Glass et al. [18] also reported that a
decline in mammography activity may explain some of the drop. In another US study, Kerli-
kowske et al. [19] suggested that a decline in screening mammography is unlikely to account
for the recent decline in US breast cancer incidence rates. However, Kerlikowske et al. [19] did
not report mammography screening rates, and changes in these rates may explain the change
in the breast cancer rate because of overdiagnosis related to screening.
Ioannidis [20,21] noted that contradictions and initially stronger effects are frequent in
highly cited clinical research/interventions and their outcomes, especially in non-randomized
studies, and suggested to study possible causal mechanisms. Our study shows that a realistic
combination of time-varying rates observed in a randomized trial may yield similar results as
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those found in recent observational studies. We show that time-varying hormone effects triple
the effect of CHT in an observational study design and this may explain Ioannidis observations.
Consequently the findings of the observational studies of increased incidence rates of breast
cancer due to use of CHTs may be spurious and biased.
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